

UCLA

UCLA Previously Published Works

Title

Parental age and the risk of childhood acute myeloid leukemia: results from the Childhood Leukemia International Consortium

Permalink

<https://escholarship.org/uc/item/07d2m2d4>

Authors

Panagopoulou, Paraskevi

Skalkidou, Alkistis

Marcotte, Erin

et al.

Publication Date

2019-04-01

DOI

10.1016/j.canep.2019.01.022

Peer reviewed

Parental age and the risk of childhood acute myeloid leukemia: results from the Childhood

Leukemia International Consortium

Authors

Paraskevi Panagopoulou^{a*}, Alkistis Skalkidou^{b*}, Erin Marcotte^{c*}, Friederike Erdmann^{d,e}, Xiaomei Ma^f, Julia E Heck^g, Anssi Auvinen^h, Beth A Mueller^{i,j*}, Logan G Spector^k, Eve Roman^l, Catherine Metayer^m, Corrado Magnaniⁿ, Maria S Pombo-de-Oliveira^{o*}, Michael E Scheurer^p, Ana M Mora^q, John D Dockerty^{r*}, Johnni Hansen^s, Alice Y Kang^m, Rong Wang^f, David R Doodyⁱ, Eleanor Kane^l, Joachim Schüz^d, Christos Christodoulakis^a, FRECCLE group^{**}, NARECHEM-ST group^{***}, Evangelia Ntzani^{t, u}, EleniTh Petridou^{a, v*}

*Core Writing Group

**FRECCLE group: Finnish Register-Based Case-Control Study Of Childhood Leukemia. Atte Nikkilä, Olli Lohi

***NARECHEM-ST group: Margarita Baka, Maria Moschovi, Vassilios Papadakis, Sophia Polychronopoulou, Maria Kourti, Emmanuel Hatzipantelis, Eftichia Stiakaki, Helen Dana, Evdoxia Bouka.

Author affiliations:

^a Department of Hygiene, Epidemiology and Medical Statistics, Medical School, National and Kapodistrian University of Athens, Athens, Greece

^b Department of Women's and Children's Health, Uppsala University, Uppsala, Sweden

^c Division of Epidemiology & Clinical Research, Department of Pediatrics, University of Minnesota, Minneapolis, Minnesota, US

^d International Agency for Research on Cancer, Section of Environment and Radiation, Lyon, France

^e Danish Cancer Society Research Center, Childhood Cancer Research Group, Copenhagen, Denmark

^f Department of Chronic Disease Epidemiology, Yale School of Public Health, Cancer Prevention and Control, Yale Comprehensive Cancer Center, Yale School of Medicine, Connecticut, US

^g Department of Epidemiology, School of Public Health, University of California, Los Angeles, California, USA

^h Faculty of Social Sciences, University of Tampere, Tampere, Finland

ⁱ Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, US

^j Department of Epidemiology, School of Public Health, University of Washington, Seattle, Washington, US

^k Division of Epidemiology & Clinical Research, Department of Pediatrics, University of Minnesota, Minneapolis, Minnesota, US

^l Epidemiology and Cancer Statistics Group, Department of Health Sciences, University of York, Heslington, York, United Kingdom

^m School of Public Health, University of California, Berkeley, Berkeley, California, US

ⁿ Cancer Epidemiology Unit, Department of Translational Medicine, CPO Piedmont and University of Eastern Piedmont, Novara, Italy

^o Pediatric Hematology-Oncology Program, Instituto Nacional de Cancer, Rio de Janeiro, Brazil

^p Baylor College of Medicine, Department of Pediatrics Texas Children's Cancer Center, Texas US

^q Central American Institute for Studies on Toxic Substances (IRET), Universidad Nacional, Heredia, Costa Rica

^r Department of Preventative and Social Medicine, Dunedin School of Medicine, University of Otago, Dunedin, New Zealand

^s Danish Cancer Society Research Center, Copenhagen, Denmark

^t Department of Hygiene and Epidemiology, School of Medicine, University of Ioannina, Greece.

^u Center for Evidence Synthesis in Health, Brown University School of Public Health, Providence, RI, USA

^v Clinical Epidemiology Unit, Department of Medicine, Karolinska Institute, Stockholm Sweden.

Word Count: Abstract: 250 words. **Total manuscript:** 3002 words. **Highlights:** 71 words

Key words: infant acute myeloid leukemia; childhood cancer; epidemiology; maternal age; paternal age; risk factors.

Abbreviations: AML: acute myeloid leukemia; ALL: acute lymphoblastic leukemia; CLIC: Childhood Leukemia International Consortium; RCC: registry-based case-control study; QCC: questionnaire-based case-control study; CI: confidence interval; OR: Odds ratios; COG: Children's Oncology Group.

Corresponding author:

Eleni Th. Petridou MD, MPH, PhD

Professor of Epidemiology and Preventive Medicine

Department of Hygiene, Epidemiology and Medical Statistics, Medical School, National and

Kapodistrian University of Athens, 75 Mikras Asias Str, Athens Greece 11527

Email: epetrid@med.uoa.gr; Tel +30 210-7462187, Fax +30 210-7462105

ABSTRACT

Background: Parental age has been associated with several childhood cancers, albeit the evidence is still inconsistent.

Aim: To examine the associations of parental age at birth with acute myeloid leukemia (AML) among children aged 0-14 years using individual-level data from the Childhood Leukemia International Consortium (CLIC) and non-CLIC studies.

Material/Methods: We analyzed data of 3182 incident AML cases and 8377 controls from 17 studies [seven registry-based case-control (RCC) studies and ten questionnaire-based case-control (QCC) studies]. AML risk in association with parental age was calculated using multiple logistic regression, meta-analyses, and pooled-effect estimates. Models were stratified by age at diagnosis (infants <1 year-old vs. children 1-14 years-old) and by study design, using five-year parental age increments and controlling for sex, ethnicity, birthweight, prematurity, multiple gestation, birth order, maternal smoking and education, age at diagnosis (cases aged 1-14 years), and recruitment time period.

Results: Adjusted odds ratios (ORs) and 95% confidence intervals (CIs) derived from RCC, but not from the QCC, studies showed a higher AML risk for infants of mothers ≥ 40 -year-old (OR = 6.87; 95% CI: 2.12-22.25). There were no associations observed between any other maternal or paternal age group and AML risk for children older than one year.

Conclusions: An increased risk of infant AML with advanced maternal age was found using data from RCC, but not QCC studies; no parental age-AML associations were observed for older children.

INTRODUCTION

Acute myeloid leukemia (AML) is very rare in children accounting for about 15% of all childhood leukemia cases[1]. Its incidence varies significantly between and within countries, continents and ethnic groups[1,2]. This variability could be due to genetic, environmental[3] or socioeconomic factors, although underascertainment of cases likely plays a role. AML incidence is higher in infants less than one year of age, dropping in childhood to gradually increase again in adolescents and young adults[3]. Heterogeneity by disease subtype and biologic characteristics is noticeable, especially among infants[4].

Large collaborative studies have examined the association of AML with several potential risk factors such as demographic and genetic characteristics[3], socioeconomic indices[5], environmental exposures (e.g. solvents[6], ambient air pollution[7], pesticides[8]), vitamins[9], infections, and birth characteristics [including anthropometrics[10], gestational age[11], birth order, and method of delivery (vaginal vs. cesarean)[12]), with findings that vary across studies for most factors. In contrast, associations of genetic syndromes (i.e., Down syndrome, Fanconi anemia, Bloom syndrome) with AML have been well established[3], but explain only a small percentage of all cases.

Several studies have examined the association between parental age and increased risk of various types of childhood cancer[13,14,15,16], acute leukaemia[17,18] and infant AML[19] in particular, with inconsistent results. We sought to elucidate this association by using the largest existing individual-level AML dataset. Here we report combined analyses of data from 17 studies; 13 participating in the Childhood Leukemia International Consortium (CLIC) across nine countries in Europe, America, and New Zealand and another four non-CLIC studies. To take into account the possible selection bias of some included case-control (CC) studies which required active participation[20], we analysed the data of registry-based case-control(RCC)

studies separately from those of questionnaire-based case-control(QCC) studies.

METHODS

Study designs and availability of data

CLIC was established in 2007 to promote investigations on the association of childhood leukemia with rare exposures, gene-environment interactions through pooling of data from independent studies internationally. Thirteen CLIC studies provided data. In order to further increase the size of our data four non-CLIC registry-based studies were also included (US, California State, CCLRP; US, Minnesota State; US, New York State; US, Texas State) and provided individual-level data from large-scale record-linkage of national or statewide population-based administrative registries. Overall, seven registry-based CC and 10 questionnaire-based CC studies were included in this pooling project. Of note, some of the questionnaire-based CC studies involve also subjects from population-based registries, at least with regards to case recruitment.

Adjusted summary estimates were provided by the California State registry-based CC study, whereas three State cancer registries (Minnesota, New York -excluding New York City-, Texas) provided pooled analysis-derived estimates (Supplementary Table 1). Questionnaire-based CC studies conducted in Brazil, Costa Rica, Germany, Greece, Italy, New Zealand, UK, and the U.S. (California State, COG-E14, Texas State) provided individual-level data on the exposures of interest for cases and controls and disease-related information. The term QCC studies refers to the method of data collection via questionnaire and includes interview-based studies. Details on data collection for each study are reported elsewhere[21].

The age range of cases and controls at diagnosis or recruitment was 0-14 years. Children with Down syndrome –known to be associated with advanced maternal age- and an established

strong risk factor for the development of leukemia[22,23] - were excluded from these analyses from both cases and controls, especially because this was an exclusion criterion for control enrollment in some studies.

Data collection and harmonization

Variables contributed by the individual studies were reviewed and harmonized. Whenever controls were frequency-matched on age [Brazil, Costa Rica, Denmark, Germany, New Zealand, Texas CC study, and the five RCC studies from the U.S.(States of California, Minnesota, New York, Texas, and Washington)], a maximum of three controls per case were randomly selected. Percentages of missing values for each variable per study were mostly small (Supplementary Table 2). For Denmark and Finland where ethnicity was not available, the data provider assigned the category Caucasian whereas for Costa Rica the category non-Caucasian was used.

Statistical analyses

Associations of childhood AML with paternal and maternal age were first examined using cubic spline models for each study with individual-level data but results were inconsistent across studies. Based on two recent publications[17,19] in order to explore the impact of extremely young and very advanced parental ages, six age categories were defined (<20, 20-24, 25-29 [reference], 30-34, 35-39, ≥40 years) for maternal and paternal age.

Covariates included in the multivariable models were literature-derived, determined *a priori*, and categorized as follows: index child's age at diagnosis (<1, 1-4, 5-9, 10-14 years) (used as a covariate only for analyses among 1-14 year olds); sex (male/female); child's ethnicity (Caucasian/non-Caucasian), birthweight (500g increments; lowest and highest recorded weights were 501 gr and 6001 gr respectively); maternal education (low: secondary education not completed, intermediate: secondary education completed, high: college, university or

higher degree); maternal smoking during pregnancy (yes/no); preterm birth (gestational age <37 weeks: yes/no), multiple gestation (yes/no), birth order (1, 2, ≥3), and time period of diagnosis/recruitment (1968-1993, 1994-2003, 2004-2015). Paternal and maternal age variables were first included in the models separately and then simultaneously (i.e., mutual adjustment).

Risk estimates were calculated using maximally-adjusted logistic regression models. Because of the known different biological characteristics of infant AML, models were stratified by age at diagnosis (<1 year of age vs. 1-14 years) and also by study design (RCC vs. QCC) and analyses were conducted separately. Further analyses for AML in children <2 years-old were also performed. Variables with >20% missing values were excluded from study-specific models [17]. Data from the 10 questionnaire-based CC studies were pooled using unconditional logistic regression models controlling for individual study. Meta-analysis of individual study-effect estimates was not feasible in several CC studies due to paucity of data for some of parental age groups for the analysis of infant AML cases (<1 year-old). For the tabulated, registry-based case control, linkage-derived data meta-analysis was performed. Among the seven registry-based CC studies, two effect estimates were supplied: one for the California State RCC study, a second for the combined effect estimate for Minnesota, New York and Texas States RCC studies. A third effect estimate was calculated from the pooled individual-level data for the remaining three registry-based CC studies (Washington State, Finland and Denmark). The three effect estimates were then combined using a random-effects meta-analysis, with heterogeneity of the estimates tested using Cochran Q and I^2 statistic (statistical significance was set at p -value <0.10, derived from the Cochran Q test). The supplied effect estimates were adjusted for the same variables as those that we used in

the raw data. Statistical analyses were conducted with SAS 9.4 version and STATA 14.1 version.

RESULTS

Characteristics of the study population

A total of 3182 childhood (0-14 years) AML cases and 8377 controls were included in the analyses. The seven registry-based NCC studies contributed data for 1888 cases (285 infants) and 6102 controls (922 infants); the 10 questionnaire-based CC studies contributed 1294 cases (186 infants) and 2275 controls (402 infants). Enrollment periods of diagnosis or recruitment varied by study and spanned from 1968 to 2015. Characteristics of cases and controls stratified by age group (<1 year vs. 1-14 years) and by study design (RCC vs. QCC) are presented in Table 1. Differences in the distributions by sex, ethnicity, and time period at diagnosis in the infant dataset could be attributed to the differential distributions of these characteristics among subjects from Brazil, during the 1998-2015 period. When the Brazilian data were excluded (data not shown), the distributions became similar. Overall, boys outnumbered girls in the 1-14 year age group. Caucasians represented 65% and 73% of participants (cases and controls together) in RCC studies and QCC studies, respectively. The distribution of maternal and paternal age at childbirth of the controls was highly variable across studies (Supplementary Figure 1).

Results by study design

Table 2 shows the results from the meta-analysis of the RCC studies and the multivariable analysis of the QCC studies. The meta-analysis of RCC studies indicated an almost seven-fold increase in AML risk for infants whose mothers were older than 40 years-old compared to infants whose mothers were 25-29 years-old ($OR_{NCC} = 6.87$, 95% CI=2.12-22.25 - adjusted for paternal age). An increased AML risk for infants whose mothers were 40 years-old or older

was also observed in the multivariable analysis of the QCC studies, but did not reach statistical significance and confidence intervals were wide (OR_{cc}=3.31, 95% CI =0.64-16.98). None of the remaining maternal age groups were associated with AML risk neither among infants nor among older children. Analyses of the effect of paternal age showed no statistically significant associations with the risk for childhood AML in infants or older children.

DISCUSSION

In this study, the effect of parental age -a well-defined exposure variable- on the incidence of childhood AML was assessed using the largest dataset of newly diagnosed children with AML worldwide. A seven-fold increase in risk of AML before the age of one year was found for children born to mothers older than 40 years compared to mothers aged 25-29 years. No association of paternal age with AML risk was found in RCC or QCC studies.

The association of childhood cancer and leukemia with parental age has been previously investigated [13,14,15]. It has been shown that advanced parental age is associated with increased ALL risk in the offspring [17]. However, fewer studies have focused solely on the risk of AML. Recently, Marcotte et al, studied this association and found that maternal age >40 years significantly increased the risk of infant AML (OR:4.8, 95%CI:1.8-12.76), whereas paternal age <20 years was associated with an increased risk of infant ALL (OR:3.69, 95%CI: 1.62-8.41)[19]. The size of the effect of advanced maternal age was similar to that in the present study. Moreover, despite the relatively high effect magnitude when using multiplicative measures of association, the absolute risk increase as well as the derived attributable fractions remain small.

Similarly, in a recent study by Sergentanis et al, maternal age was found to be significantly

associated with an increased risk of childhood AML in a U-shaped manner as both oldest (>40 years) and youngest (<20 years) ages were associated with a 23% increase in AML risk[18]. Also in these analyses, only fathers in the youngest age-group had a 28% increase in risk of having a child with AML[18]. In contrast to the study by Sergentanis et al, where results derived from the meta-analysis of 77 published case-control studies, in the current analysis, the participating studies contributed individual-level data which allowed more detailed analyses with simultaneous adjustment for maternal and paternal age. It also allowed subgroup analyses by age at diagnosis, which proved to be particularly important given the striking association of infant AML with advanced maternal age that emerged. The fact that the association of younger paternal age with AML reported by Sergentanis et al. was not replicated in the present study, could be attributed to methodological differences such as the use of data from RCC studies and not QCC studies which require active participation, the use of adjusted estimates, and the availability of primary data regarding age.

The association of advanced maternal age with infant AML may be explained by several mechanisms. Infant leukemia is characterized by high prevalence of MLL gene rearrangements (50-80% of infant ALL and 34-50% of infant AML compared to 6% and 14% in older children, respectively)[4,24,25]. In addition, secondary AML after chemotherapy with DNA topoisomerase-II inhibitors (e.g. epipodophyllotoxins) usually harbors a large number of MLL mutations[26]. It has been suggested that dietary exposure of pregnant women to naturally occurring topoisomerase-II inhibitors (e.g. in beans, fresh and canned vegetables, fruit, soy, coffee, tea, cocoa, and wine)[27] may contribute to the increased incidence of AML among their infants[28]. In the present study, no data on the MLL gene status of the cases were available, so it was not possible to assess this association. Further research incorporating genetic information should be conducted to better elucidate associations of

maternal and paternal age with MLL mutation status.

Other carcinogenic effects and *de novo* mutations, associated with advanced maternal age, could also be involved in the etiology of infant AML. In a study of MLL-negative infant leukemia, where whole genome sequencing was performed for infant-mother pairs, a high burden of germline genetic variation in the MLL3 gene was found[29]. More specifically, it was shown that 100% of infant AML and 50% of infant ALL cases were compound heterozygotes of MLL3[29]. Nearly half of the germline variation in the infants could be tracked to maternal alleles, and it was suggested that the additional germline variation was either of paternal or *de novo* origin or both[29].

The sizeable positive association of infant AML with advanced maternal age raises the question of the role of fertility treatments. Although, previous studies have demonstrated the association between assisted reproduction, especially *in vitro* fertilization, and early onset ALL, no association was found for AML[30,31]. Notably, ages at which women and men have their first offspring have increased over the last decades with a rising percentage of parents older than 40 years[32]. This increase in childbearing age could be potentially associated with increased frequency of *de novo* mutations[33,34], and decreased methylation levels in the offspring of older parents via the same mechanism that causes increased frequency of chromosomal abnormalities[35,36,37]. In this study, cases and controls with trisomy 21 were excluded from the analyses. Review of the data before exclusion revealed that the percentage of controls with Down syndrome was around the expected 0.1% which can be used as a robust indicator of completeness of registration.

In order to make better use of the available individual-level data and to reduce potentially biased findings, studies were grouped by study design (RCC vs. QCC) and analysed separately in the present study. In the methodologically less prone to bias, RCC a strong association

between advanced maternal age and infant AML was observed, whereas no such association was found in children diagnosed at older ages. Self-reported information in questionnaire- or interview-based CC studies raise a concern for bias, as does the possibility that controls may not fully represent the underlying population since there is substantial potential for selection bias [20]. In RCC studies, this likelihood is diminished as controls are randomly selected from population registers, and may better represent the source population from which cases rose. This strength may also help explain why the associations with maternal age differed between the two types of study.

In the current analyses, it was not possible to determine how well the variable “parental age” (recorded in RCC studies or reported in QCC studies) reflected the age of the biological parents at the time of birth of the index child and not the age of the legal guardians.

However, as adoption is rare (e.g. 0.6% in the nationwide Danish study), it is not anticipated that non-availability of the age of the biological parents would have affected our findings[15].

In addition, in the Washington State RCC study, the biological parent’s age is recorded even in the case of adoption, whereas in the UKCC and the CCLS California studies adopted children are not included unless the biological parents are available for interview. Therefore, this type of misclassification is unlikely. Finally, as the median rate of paternal discrepancy (when a child is identified as being biologically fathered by someone other than the man who believes he is the father) is low (3.7% internationally) any misclassification of paternal age would likely have a negligible effect[38].

The variability in the distribution of parental age of controls between countries could have possibly introduced some unmeasurable error. In Greece, for example, the maternal age distribution among controls seemed to follow the national estimates, but there are no national statistics on the paternal age distribution. Likewise, the parental age distribution in

the Italian study (SETIL) followed the national population pattern and seemed to yield results similar to those of a cohort study[39]. Finally, to eliminate the potential effect of collinearity between maternal and paternal age, the two variables were mutually adjusted for. Although the roles of maternal and paternal age cannot be easily disentangled our analysis has demonstrated that advanced maternal age is by it's own right a significant risk factor for infant AML.

The very large volume of primary data of AML cases that have been compiled from all the participating CLIC and non-CLIC studies is one of this study's main strengths. Although several studies have examined the association of parental age with leukemia [13-17,39] and the interplay with other possible factors like birth order[40] the numbers are small for AML. For infant AML, in particular they are even smaller. Another strength is the use of population-based health records' linkage in the RCC studies which aimed at reducing a potential selection bias that might have affected the participating QCC studies which seem to be more vulnerable since participation of controls is often affected by parental and more specifically paternal age[20].

Information on MLL rearrangement status, use of assisted reproductive technologies, and AML subtypes (M0-7) was not collected by most of the participating studies; therefore, no conclusions on the biological mechanisms underlying the association of advanced maternal age and infant AML could be reached. Additional limitations of the present analyses include differences in data collection methodology for cases and controls by country, as well as the prolonged and variable data collection periods for each study.

In conclusion, advanced maternal age was found to be associated with AML in infants but not in other age-groups. Extremely young or advanced paternal age was not associated with AML in any age group. Inclusion of genetic information in future studies will further elucidate the

mechanisms that underlie the observed association and to achieve this international collaboration is required.

Acknowledgements

The CLIC studies thank the families for their consent and participation, the study staff, interviewers and pediatric oncologists for their support. Acknowledgements by study site as well as sources of funding are shown in Supplementary Table 3.

COMPLIANCE WITH ETHICAL STANDARDS

Conflict of interest

The authors declare that they have no conflict of interest.

Declarations of interest.

None.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committeeS and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.

REFERENCES

- [1] Steliarova-Foucher E, Colombet M, Ries LAG, Hesselning P, Moreno F, Shin HY, Stiller CA, editors (2017). **International Incidence of Childhood Cancer, Volume III** (electronic version). Lyon, France: International Agency for Research on Cancer. Available from: <http://iicc.iarc.fr/results/> (Accessed: 30/06/2018).

- [2] Redner A, Kessel R. **Chapter 19: Acute Myeloid Leukemia.** In: Lanzkowski P, Lipton JM, Fish JD (Eds) Lanzkowski's Manual of Paediatric Hematology and Oncology. Sixth Edition. London: Academic Press. 2016; 390-406.
- [3] Puumala SE, Ross JA, Aplenc R, Spector LG. **Epidemiology of Childhood Acute Myeloid Leukemia.** *Pediatr Blood Cancer* 2013; 60: 728–33. doi: 10.1002/pbc.24464.
- [4] De Rooij JDE, Zwaan CM, van den Heuvel-Eibrink M. **Pediatric AML: From Biology to Clinical Management.** *J Clin Med* 2015; 4: 127-49. doi:10.3390/jcm4010127
- [5] Adam M, Kuehni CE, Spoerri A, Schmidlin K, Gumy-Pause F, Brazzola P, Probst-Hensch N, Zwahlen M. **Socioeconomic status and childhood leukemia incidence in Switzerland.** *Front Oncol* 2015; 5; 139. doi: 10.3389/fonc.2015.00139
- [6] Scélo G, Metayer C, Zhang L, Wiemels JL, Aldrich MC, Selvin S, Month S, Smith MT, Buffler PA. **Household exposure to paint and petroleum solvents, chromosomal translocations, and the risk of childhood leukemia.** *Environ Health Perspect* 2009; 117: 133–9. doi: 10.1289/ehp.11927.
- [7] Raaschou-Nielsen O, Hvidtfeldt UA, Roswall N, Hertel O, Poulsen AH, Sørensen M. **Ambient benzene at the residence and risk for subtypes of childhood leukemia, lymphoma and CNS tumor.** *Int J Cancer* 2018; 143 :1367-73. doi: 10.1002/ijc.31421.
- [8] Bailey HD, Fritschi L, Infante-Rivard C, Glass DC, Miligi L, Dockerty JD, Lightfoot T, Clavel J, Roman E, Spector LG, Kaatsch P, Metayer C, Magnani C, Milne E, Polychronopoulou S, Simpson J, Rudant J, Sidi V, Rondelli R, Orsi L, Kang AY, Petridou E, Schüz J. **Parental occupational pesticide exposure and the risk of childhood leukemia in the offspring: findings from the childhood leukemia international consortium.** *Int J Cancer* 2014; 135: 2157-72. doi: 10.1002/ijc.28854.

- [9] Metayer C, Milne E, Dockerty JD, Clavel J, Pombo-de-Oliveira MS, Wesseling C, Spector LG, Schüz J, Petridou E, Ezzat S, Armstrong BK, Rudant J, Koifman S, Kaatsch P, Moschovi M, Rashed WM, Selvin S, McCauley K, Hung RJ, Kang AY, Infante-Rivard C. **Maternal supplementation with folic acid and other vitamins and risk of leukemia in offspring: a Childhood Leukemia International Consortium study.** *Epidemiology* 2014; 25: 811–22. doi: 10.1097/EDE.000000000000141.
- [10] Oksuzyan S, Crespi CM, Cockburn M, Mezei G, Kheifets L. **Birth weight and other perinatal characteristic and childhood leukemia in California.** *Cancer Epidemiol* 2012; 36: e359–65. doi: 10.1016/j.canep.2012.08.002
- [11] Wang YF, Wu LQ, Liu YN, Bi YY, Wang H. **Gestational age and childhood leukemia: A meta-analysis of epidemiologic studies.** *Hematology* 2018; 23: 253-62. doi: 10.1080/10245332.2017.1396056.
- [12] Marcotte EL, Thomopoulos TP, Infante-Rivard C, Clavel J, Petridou ET, Schüz J, Ezzat S, Dockerty JD, Metayer C, Magnani C, Scheurer ME, Mueller BA, Mora AM, Wesseling C, Skalkidou A, Rashed WM, Francis SS, Ajrouche R, Erdmann F, Orsi L, Spector LG. **Caesarean delivery and risk of childhood leukaemia: a pooled analysis from the Childhood Leukemia International Consortium (CLIC).** *Lancet Haematol* 2016; 3: e176-85. doi: 10.1016/S2352-3026(16)00002-8.
- [13] Johnson KJ, Carozza SE, Chow EJ, Fox EE, Horel S, McLaughlin CC, Mueller BA, Puumala SE, Reynolds P, Von Behren J, Spector LG. **Parental age and risk of childhood cancer: a pooled analysis.** *Epidemiology* 2009; 20: 475–83. doi:10.1097/EDE.0b013e3181a5a332.
- [14] Wang R, Metayer C, Morimoto L, Wiemels JL, Yang J, DeWan AT, Kang A, Ma X. **Parental Age and Risk of Pediatric Cancer in the Offspring: A Population-Based Record-Linkage Study in California.** *Am J Epidemiol* 2017; 186: 843-56. doi: 10.1093/aje/kwx160

- [15] Contreras ZA, Hansen J, Ritz B, Olsen J, Yu F, Heck JE. **Parental age and childhood cancer risk: A Danish population-based registry study.** *Cancer Epidemiol* 2017; 49: 202-15. doi:10.1016/j.canep.2017.06.010
- [16] Urhoj SK, Raaschou-Nielsen O, Hansen AV, Mortensen LH, Andersen PK, Nybo Andersen AM. **Advanced paternal age and childhood cancer in offspring: A nationwide register-based cohort study.** *Int J Cancer* 2017; 140: 2461-72. doi:10.1002/ijc.30677.
- [17] Petridou ET, Georgakis MK, Erdmann F, Ma X, Heck JE, Auvinen A, Mueller BA, Spector LG, Roman E, Metayer C, Magnani C, Pombo-de-Oliveira MS, Ezzat S, Scheurer ME, Mora AM, Dockerty JD, Hansen J, Kang AY, Wang R, Doody DR, Kane E, Rashed WM, Dessypris N, Schüz J, Infante-Rivard C, Skalkidou A. **Advanced parental age as risk factor for childhood acute lymphoblastic leukemia: results from studies of the Childhood Leukemia International Consortium.** *Eur J Epidemiol* 2018; May 14. doi: 10.1007/s10654-018-0402-z. [Epub ahead of print]
- [18] Sergentanis TN, Thomopoulos TP, Gialamas SP, Karalexi MA, Biniaris-Georgallis SI, Kontogeorgi E, Papathoma P, Tsilimidos G, Skalkidou A, Iliadou AN, Petridou ET. **Risk for childhood leukemia associated with maternal and paternal age.** *Eur J Epidemiol* 2015; 30: 1229-61. doi:10.1007/s10654-015-0089-3.
- [19] Marcotte EL, Druley TE, Johnson KJ, Richardson M, von Behren J, Mueller BA, Carozza S, McLaughlin C, Chow EJ, Reynolds P, Spector LG. **Parental Age and Risk of Infant Leukaemia: A Pooled Analysis.** *Paediatr Perinat Epidemiol* 2017; 31: 563-72. doi:10.1111/ppe.12412.
- [20] Schuz J. **Non-response bias as a likely cause of the association between young maternal age at the time of delivery and the risk of cancer in the offspring.** *Paediatr Perinat Epidemiol* 2003; 17: 106-12

- [21] Metayer C, Milne E, Clavel J, Infante-Rivard C, Petridou E, Taylor M, Schüz J, Spector LG, Dockerty JD, Magnani C, Pombo-de-Oliveira MS, Sinnett D, Murphy M, Roman E, Monge P, Ezzat S, Mueller BA, Scheurer ME, Armstrong BK, Birch J, Kaatsch P, Koifman S, Lightfoot T, Bhatti P, Bondy ML, Rudant J, O'Neill K, Miligi L, Dessypris N, Kang AY, Buffler PA. **The Childhood Leukemia International Consortium.** *Cancer Epidemiol* 2013; 37: 336-47. doi: 10.1016/j.canep.2012.12.011
- [22] Cantor AB. **Myeloid Proliferations Associated with Down Syndrome.** *J Hematop* 2015; 8: 169-76. doi: 10.1007/s12308-014-0225-0
- [23] Tomizawa D, Kolb EA. **Down syndrome and AML: where do we go from here?** *Blood.* 2017 Jun 22. 129 :3274-3275. doi: 10.1182/blood-2017-04-780031
- [24] Greaves MF, Wiemels J. **Origins of chromosome translocations in childhood leukemia.** *Nat Rev Cancer* 2003; 3: 639-49. doi: 10.1038/nrc1164
- [25] Ross JA, Linabery AM, Blommer CN, Langer EK, Spector LG, Hilden JM, Heerema NA, Radloff GA, Tower RL, Davies SM. **Genetic variants modify susceptibility to leukemia in infants: a Children's Oncology Group report.** *Pediatr Blood Cancer.* 2013 Jan; 60:31-34. doi: 10.1002/pbc.24131.
- [26] Sandler ES, Friedman DJ, Mustafa MM, Winick NJ, Bowman WP, Buchanan GR. **Treatment of children with epipodophyllotoxin-induced secondary acute myeloid leukemia.** *Cancer* 1997; 79: 1049–54.
- [27] Ross JA, Potter JD, Reaman GH, Pendergrass TW, Robison LL. **Maternal exposure to potential inhibitors of DNA topoisomerase II and infant leukemia (United States): A report from the Children's Cancer Group.** *Cancer Causes Control* 1996; 7:581–90.
- [28] Spector LG, Xie Y, Robison LL, Heerema NA, Hilden JM, Lange B, Felix CA, Davies SM, Slavin J, Potter JD, Blair CK, Reaman GH, Ross JA. **Maternal diet and infant leukemia.**

The DNA topoisomerase II inhibitor hypothesis: a report from the children's oncology group. *Cancer Epidemiol Biomarkers Prev* 2005; 14: 651-55. doi: 10.1158/1055-9965.EPI-04-0602

[29] Valentine MC, Linabery AM, Chasnoff S, Hughes AE, Mallaney C, Sanchez N, Giacalone J, Heerema NA, Hilden JM, Spector LG, Ross JA, Druley TE. **Excess congenital non-synonymous variation in leukemia-associated genes in *MLL*- infant leukemia: a Children's Oncology Group report.** *Leukemia* 2014; 28: 1235-41. doi: 10.1038/leu.2013.367.

[30] Petridou ET, Sergentanis TN, Panagopoulou P, Moschovi M, Polychronopoulou S, Baka M, Pourtsidis A, Athanassiadou F, Kalmanti M, Sidi V, Dessypris N, Frangakis C, Matsoukis IL, Stefanadis C, Skalkidou A, Stephansson O, Adami HO, Kieler H. **In vitro fertilization and risk of childhood leukemia in Greece and Sweden.** *Pediatr Blood Cancer* 2012; 58: 930-6. doi: 10.1002/pbc.23194

[31] Hargreave M, Jensen A, Nielsen TS, Colov EP, Andersen KK, Pinborg A, Kjaer SK. **Maternal use of fertility drugs and risk of cancer in children--a nationwide population-based cohort study in Denmark.** *Int J Cancer* 2015;136:1931-9. doi: 10.1002/ijc.29235

[32] Martin JA, Hamilton BE, Osterman MJ, Driscoll AK, Mathews TJ. **Births: Final Data for 2015.** *Natl Vital Stat Rep.* 2017; 66:1.

[33] Nybo-Andersen AM, Urhoj, SK. **Is advanced paternal age a health risk for the offspring?** *Fertil Steril* 2017; 107: 312-8. doi:10.1016/j.fertnstert.2016.12.019

[34] Wong WS, Solomon BD, Bodian DL, Kothiyal P, Eley G, Huddleston KC, Baker R, Thach DC, Iyer RK, Vockley JG, Niederhuber JE. **New observations on maternal age effect on germline de novo mutations.** *Nat Commun* 2016; 7: 10486. doi: 10.1038/ncomms10486.

- [35] Rahbari R, Wuster A, Lindsay SJ, Hardwick RJ, Alexandrov LB, Turki SA, Dominiczak A, Morris A, Porteous D, Smith B, Stratton MR; UK10K Consortium, Hurles ME. **Timing, rates and spectra of human germline mutation.** *Nat Genet.* 2016 Feb;48(2):126-133. doi: 10.1038/ng.3469.
- [36] Adkins RM, Thomas F, Tylavsky FA, Krushkal J. **Parental ages and levels of DNA methylation in the newborn are correlated.** *BMC Med Genet* 2011; 12:47. doi: 10.1186/1471-2350-12-47.
- [37] Wilcox AJ, Sandler DP, Everson RB. **Using father's age to explore the role of germcell mutation as a cause of human cancer.** *Int J Epidemiol* 1988; 17: 469–71.
- [38] Bellis MA, Hughes K, Hughes S, Ashton J. **Measuring paternal discrepancy and its public health consequences.** *J Epidemiol Community Health* 2005; 59: 749–54. doi:10.1136/jech.2005.036517.
- [39] Maule MM, Vizzini L, Merletti F, Magnani C, Pastore G, Richiardi L. **Parental age and risk of acute lymphocytic leukaemia and embryonal tumours in the Piedmont Region, Italy.** *Int J Epidemiol* 2007; 36: 691–2. doi: 10.1093/ije/dym115.
- [40] Paltiel O, Lemeshow S, Phillips GS, Tikellis G, Linet MS, Ponsonby AL, Magnus P, Håberg SE, Olsen SF, Granström C, Klebanoff M, Golding J, Herceg Z, Ghantous A, Hirst JE, Borkhardt A, Ward MH, Holst Sjøgaard S, Dwyer T. **The association between birth order and childhood leukemia may be modified by paternal age and birth weight. Pooled results from the International Childhood Cancer Cohort Consortium (I4C).** *Int J Cancer* 2018 Aug 11. doi: 10.1002/ijc.31635. [Epub ahead of print]

Highlights

- Maternal age older than 40 years is a risk factor for AML in children less than one year-old.
- A 7-fold increase in AML risk was found for infants with maternal age ≥ 40 years.
- Paternal age is not a risk factor for AML in children in any age group.
- Maternal age less than 40 years is not a risk factor for AML in children in any age group.

Table 1. Characteristics of acute myeloid leukemia (AML) cases and controls by study design and age at diagnosis (<1 year, 1-14 years)

		Age at diagnosis														
		<1 year						1-14 years								
Study design →	Registry-based CC ^a (no of studies=7)				Questionnaire-based CC (no of studies =10)				Registry-based CC (no of studies =7)				Questionnaire-based CC (no of studies =10)			
	AML cases N=285		Controls N=922		AML cases N=186		Controls N=402		AML cases N=1603		Controls N=5180		AML cases N=1108		Controls N=1873	
Variables ↓	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%
Index child's age at diagnosis/recruitment (years)																
<1	285	100.0	922	100.0	186	100.0	402	100.0								
1-4									766	47.8	2468	47.7	456	41.2	814	43.5
5-9									389	24.3	1260	24.3	331	29.9	579	30.9
10-14									448	27.9	1452	28.0	321	28.9	480	25.6
Index child's sex																
Male	131	46.0	423	45.9	100	53.8	243	60.5	836	52.2	2719	52.5	595	53.7	977	52.2
Female	154	54.0	499	54.1	86	46.2	159	39.5	767	47.8	2461	47.5	513	46.3	896	47.8
Time period at diagnosis/recruitment																
1968-1993	96	33.7	297	32.2	67	36.0	110	27.4	493	30.8	1551	29.9	508	45.9	785	41.9
1994-2003	122	42.8	400	43.4	62	33.3	216	53.7	725	45.1	2356	45.5	390	35.2	821	43.8
2004-2015	67	23.5	225	24.4	57	30.7	76	18.9	387	24.1	1273	24.6	210	18.9	267	14.3
Index child's race																
Caucasian	181	63.5	576	62.6	149	80.1	266	66.2	1072	67.0	3395	65.6	823	74.4	1367	73.0
Non-Caucasian	104	36.5	344	37.4	37	19.9	136	33.8	529	33.0	1779	34.4	283	25.6	505	27.0
Missing	0	0.0	2	0.2	0	0.0	0	0.0	2	0.1	6	0.1	2	0.2	1	0.1
Birthweight (g)																
<2500	23	8.2	48	5.3	7	3.8	43	10.9	93	6.0	264	5.2	55	5.1	126	6.9
2500-2999	44	15.8	133	14.6	32	17.5	89	22.5	234	15.1	742	14.7	182	16.7	316	17.3
3000-3499	102	36.5	323	35.5	60	32.8	131	33.1	514	33.2	1784	35.5	368	33.8	670	36.6
3500-3999	78	28.0	287	31.6	66	36.1	105	26.5	489	31.6	1567	31.2	336	30.8	533	29.1
≥4000	32	11.5	118	13.0	18	9.8	28	7.0	219	14.1	673	13.4	148	13.6	184	10.1
Missing	6	2.1	13	1.4	3	1.6	6	1.5	54	3.4	150	2.9	19	1.7	44	2.4
Maternal education^b																
Low	42	17.4	118	14.6	42	22.8	130	32.4	170	15.5	503	14.2	294	26.8	520	28.1
Intermediate	131	54.4	462	57.1	97	52.7	210	52.4	655	59.6	2121	59.6	589	53.8	933	50.4
High	68	28.2	229	28.3	45	24.5	61	15.2	274	24.9	933	26.2	212	19.4	398	21.5
Missing	44	15.4	113	12.3	2	1.1	1	0.3	504	31.4	1623	31.3	13	1.2	22	1.2
Maternal smoking during pregnancy																
No	156	92.9	536	95.0	150	81.1	297	74.2	721	92.7	2373	92.3	856	77.9	1437	77.1

Yes	12	7.1	28	5.0	35	18.9	103	25.8	57	7.3	199	7.7	243	22.1	428	22.9
Missing	117	41.1	358	38.8	1	0.5	2	0.5	825	51.5	2608	50.3	9	0.8	8	0.4
Preterm birth^c																
No	223	86.1	772	91.6	135	91.8	208	92.9	1287	89.0	4318	91.6	908	94.1	1440	92.9
Yes	36	13.9	71	8.4	12	8.2	16	7.1	159	11.0	394	8.4	57	5.9	110	7.1
Missing	26	9.1	79	8.6	39	21.0	178	44.3	157	9.8	468	9.0	143	12.9	323	17.3
Multiple pregnancy																
No	266	97.4	865	97.6	176	96.7	385	97.5	1460	98.1	4709	97.4	1046	98.9	1695	97.7
Yes	7	2.6	21	2.4	6	3.3	10	2.5	28	1.9	124	2.6	12	1.1	39	2.3
Missing	12	4.2	36	3.9	4	2.2	7	1.7	115	7.2	347	6.7	50	4.5	139	7.4
Birth order																
1	111	39.2	370	40.3	81	44.2	174	46.6	599	38.0	2065	40.4	491	45.2	777	44.9
2	82	29.0	315	34.3	64	35.0	107	28.7	528	33.4	1705	33.3	356	32.8	584	33.8
≥3	90	31.8	233	25.4	38	20.8	92	24.7	451	28.6	1343	26.3	239	22.0	368	21.3
Missing	2	0.7	4	0.4	3	1.6	29	7.2	25	1.6	67	1.3	22	2.0	144	7.7
Maternal age at birth (years)																
<20	30	10.5	62	6.7	15	8.1	51	12.8	139	8.6	431	8.3	110	10.0	170	9.2
20-24	57	20.1	196	21.3	38	20.6	99	24.8	375	23.4	1267	24.5	285	25.9	449	24.2
25-29	73	25.7	307	33.3	59	31.9	134	33.6	503	31.4	1640	31.7	373	33.9	613	33.0
30-34	69	24.3	229	24.8	47	25.4	78	19.5	365	22.8	1229	23.7	237	21.5	435	23.4
35-39	36	12.7	109	11.8	20	10.8	31	7.8	179	11.2	507	9.8	84	7.6	162	8.7
≥40	19	6.7	19	2.1	6	3.2	6	1.5	42	2.6	106	2.0	12	1.1	27	1.5
Missing	1	0.4	0	0	1	0.5	3	0.8	0	0.0	0	0.0	7	0.6	17	0.9
Mean ± SD	28.5±6.79		28.1±5.66		27.9±6.09		26.4±5.84		27.6±5.99		27.4±5.73		26.8±5.53		27.2±5.66	
Paternal age at birth (years)																
<20	9	3.3	25	2.8	7	3.9	14	3.7	44	2.9	163	3.2	40	3.9	34	2.0
20-24	43	15.8	131	14.3	26	14.4	75	19.6	250	16.2	896	17.5	169	16.2	303	17.4
25-29	69	25.4	255	27.9	45	25.0	110	28.7	452	29.4	1512	29.5	321	30.8	503	28.9
30-34	72	26.5	256	28.0	50	27.8	103	26.9	415	27.0	1407	27.5	276	26.5	495	28.5
35-39	40	14.7	160	17.5	33	18.3	53	13.8	246	16.0	763	14.9	165	15.8	257	14.8
≥40	39	14.3	87	9.5	19	10.6	28	7.3	131	8.5	379	7.4	71	6.8	147	8.4
Missing	13	4.6	8	0.9	6	3.2	19	4.7	65	4.1	60	1.2	66	6.0	134	7.2
Mean ± SD	31.3±7.40		30.8±6.67		31.0±7.55		29.8±6.57		30.3±6.55		30.1±6.52		30.0±6.70		30.4±6.55	

^aCC: Case control; ^bMaternal education: Low: secondary education not completed; intermediate: secondary education completed; high: college, university or higher degree;

^cPreterm birth: Yes: gestational age <37 weeks; No: gestational age ≥37 weeks

Table 2. Association of maternal and paternal age with the risk of childhood (0-14 years) acute myeloid leukemia (AML): Meta-analysis derived Odds Ratios (OR) and 95% Confidence Intervals (95% CI) of the registry based case-control (RCC) studies and multiple logistic regression derived ORs of pooled data of the questionnaire based case-control (QCC) studies; maternal and paternal age are both adjusted for in the models.

Design→ Variable↓	<1 year						1-14 years					
	RCC studies ^a			QCC studies ^b			RCC studies ^a			QCC studies ^b		
	AML cases N	Controls N	OR (95% CI)	AML cases N	Controls N	OR (95% CI)	AML cases N	Controls N	OR (95% CI)	AML cases N	Controls N	OR (95% CI)
Maternal age (years)												
<20	23	62	1.44 (0.65-3.20)	12	44	0.47 (0.16-1.34)	112	399	0.93 (0.55-1.59) ^c	96	114	1.21 (0.81-1.80)
20-24	54	185	1.13 (0.70-1.82)	35	80	1.01 (0.54-1.86)	344	1202	0.92 (0.62-1.38) ^c	256	382	1.04 (0.82-1.33)
25-29	69	298	Reference	55	123	Reference	463	1579	Reference	343	517	Reference
30-34	66	229	1.53 (0.81-2.88)	45	74	1.23 (0.69-2.17)	351	1183	0.98 (0.83-1.17)	220	380	0.82 (0.64-1.05)
35-39	35	106	2.01 (0.78-5.20)	20	26	1.46 (0.63-3.35)	173	499	1.14 (0.90-1.44)	76	142	0.75 (0.52-1.08)
≥40	19	18	6.87 (2.12-22.25)	5	3	3.31 (0.64-16.98)	39	103	1.26 (0.56-2.81) ^c	9	25	0.52 (0.22-1.19)
Paternal age (years)												
<20	8	25	0.86 (0.29-2.62) ^d	7	13	2.33 (0.62-8.78)	44	162	0.91 (0.60-1.38)	37	29	1.62 (0.90-2.91)
20-24	43	128	1.16 (0.68-1.98)	23	65	1.11 (0.54-2.29)	237	841	1.01 (0.75-1.36)	161	267	0.81 (0.61-1.07)
25-29	68	248	Reference	42	104	Reference	432	1471	Reference	309	457	Reference
30-34	70	253	0.84 (0.45-1.56)	49	99	0.96 (0.54-1.70)	402	1362	0.97 (0.82-1.15)	269	446	0.96 (0.76-1.21)
35-39	39	158	0.60 (0.26-1.42)	32	44	1.29 (0.61-2.70)	243	740	1.04 (0.84-1.29)	157	231	1.12 (0.83-1.52)
≥40	38	86	0.85 (0.42-1.74)	19	25	1.21 (0.52-2.83)	124	389	0.95 (0.69-1.30)	67	130	0.86 (0.58-1.27)

RCC: registry-based case control studies; QCC: questionnaire-based case control studies; AML: acute myeloid leukemia;

In bold: statistically significant results at 0.05 level.

^aMeta-analysis derived OR comprising (a) pooled OR of the raw data from Denmark, Finland and Washington State adjusted for Caucasian vs. non-Caucasian ethnicity, birth weight, birth order and study, (b) provided pooled OR for Minnesota, New York and Texas States adjusted for Caucasian vs. non-Caucasian ethnicity, birth weight, birth order, birth year and sex and (c) provided OR for the CCRLP California study adjusted for Caucasian vs. non-Caucasian ethnicity, birth weight, birth order, pre-term birth, multiple pregnancy and study period.

^b(Applies only to the 1-14 years-old study group) Pooled Odds Ratios, maximally adjusted for age (categorical; 1-4 [reference], 5-9, 10-14 years), sex, Caucasian vs. non-Caucasian ethnicity, birth weight, birth order, maternal education, maternal smoking during pregnancy and study.

^cMeta-analyses with statistically significant heterogeneity: maternal age <20: I²:60.9% p=0.08; maternal age 20-24: I²:78.8% p=0.01; maternal age 40+: I²:66.1% p=0.05

^dBased on the meta-analysis of the CCRLP California study OR and the provided pooled OR for the Minnesota, New York, and Texas States studies

Supplementary Table 1. Childhood Leukemia International Consortium (CLIC) studies and non-CLIC studies included in the analysis of parental age and acute myeloid leukemia (AML).

Study location, Acronym	Recruitment	Cases source	Controls source/recruitment type	Cases N	Controls N
Registry based case-control studies					
Denmark	1968-2012	National Cancer Registry	National Central Population Register/ Electronic linkage	249	747
Finland	1989-2011	National Cancer Registry	National Central Population Register/ Electronic linkage	127	381
US, California State, CCLRP ¹	1988-2011	Statewide Cancer Registry	Linked State birth-hospital discharge records	846	2976
US, Washington State	1974-2014	Cancer Registry (regional 1974-1993; Statewide 1994-onwards)	Linked State birth-hospital discharge records	177	531
US, Minnesota State	1988-2004	National Cancer Registry	State birth certificates	489	1467
US, New York State	1985-2001	National Cancer Registry	State birth certificates		
US, Texas State	1990-1998	National Cancer Registry	State birth certificates		
Questionnaire-based case-control studies					
Brazil	1998-2015	Hospitals	Hospitals/Interviews	151	453
Costa Rica, CRCLS	2001-2003	Nationwide Cancer Registry	Nationwide Birth registry/Interviews	39	117
Germany, GCCR	1991-1994	National Cancer Registry	German Registries of residents (regional with national coverage)/ Interviews	98	294
Greece, NARECHEM-ST ²	1996-2015	Nationwide Clinical Cancer Registry	Hospitals/Interviews	138	138
Italy, SETIL	1998-2001	Nationwide Cancer Registry	National health system rosters/Interviews	69	97
New Zealand, NZCCS	1989-1994	National Cancer Registry, Children's Cancer Registry; Hospital Admission/Discharge system	Nationwide Birth Registry/ Interviews	22	66
UK, UKCCS	1991-1997	Nationwide General Practitioners' Registry	Nationwide General Practitioners' Registry/ Interviews	235	465
US, California State, CCLS	1995-2008	Hospitals	State Birth Registry/Interviews	133	152
US, COG ³ -E14	1989-1993	CCG clinical trials	Random digit dialing/Interviews	401	469
US, Texas State	1997-2015	Hospitals	Hospital/Interviews	8	24

¹ Effect estimates were provided for the meta analyses of record-linkage studies; ² Nationwide Registry for Childhood Hematological Malignancies and Solid Tumors; ³ Children's Oncology Group.

Supplementary Table 2. Proportion of missing values (% for both cases and controls) for each study variable by participating study.

Study location, Name	Maternal age at birth	Paternal age at birth	Child's age	Child's sex	Child's ethnicity	Birth weight	Maternal education	Maternal smoking during pregnancy	Preterm birth	Birth plurality	Birth order
Denmark	0.0	1.5	0.0	0.0	0.0	13.5	48.1	59.4	52.9	0.0	0.0
Finland	0.2	2.2	0.0	0.0	0.0	16.7	0.0	17.5	16.7	100.0	16.9
US, Washington State	0.0	9.0	0.0	0.0	1.4	0.3	45.8	27.5	11.4	0.1	1.6
US, California State CCLRP	0.0	0.0	0.0	0.0	0.0	0.0	25.2	28.2	0.0	0.0	0.0
US, Minnesota State US, New York State US, Texas State	0.0	2.9	0.0	0.0	0.0	0.1	26.4	100.0	1.9	0.1	0.1
Brazil	1.0	5.8	0.0	0.0	0.0	4.8	0.2	0.2	67.4	0.0	25.7
Costa Rica, CRCLS	0.6	18.0	0.0	0.0	0.0	11.5	1.3	1.9	0.6	100.0	0.6
Germany, GCCR	0.3	0.8	0.0	0.0	0.0	1.0	7.9	1.5	1.5	0.0	0.0
Greece, NARECHEM-ST	0.0	0.0	0.0	0.0	0.0	1.1	0.0	0.0	62.7	0.0	0.0
Italy, SETIL	0.6	1.2	0.0	0.0	0.0	0.0	0.0	0.0	38.0	0.0	0.0
New Zealand, NZCCS	0.0	2.3	0.0	0.0	0.0	1.1	0.0	0.0	1.1	0.0	0.0
UK, UKCCS	0.9	9.4	0.0	0.0	0.4	1.7	0.4	0.9	0.6	0.4	0.4
US, California State, CCLS	0.4	1.8	0.0	0.0	0.0	0.4	0.0	0.4	8.1	3.2	2.5
US, COG-E14	0.2	7.8	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0
US, Texas State	31.3	50.0	0.0	0.0	0.0	3.1	3.1	9.4	15.6	100.0	100.0

Supplementary Table 3: Acknowledgments and sources of funding per participating centre

Study	Research Investigators	Funding /Support
CRCLS (Costa Rica)	Ana María Mora, Catharina Wesseling, Patricia Monge, and Timo Partanen (Universidad Nacional, Costa Rica).	Universidad Nacional, Costa Rica
US, Californian (CCRLP)		US NIH grants R01 CA155461, R01 CA175737, P01 ES018172 and US Environmental Protection Agency RD83451101
US, California Childhood Leukemia Study (CCLS)		Funded by the National Institutes of Health, USA (R01ES009137) with additional support from the CHILDREN with CANCER, UK.
Washington State	Beth A. Mueller. We would like to acknowledge the Washington State Department of Health for data access, and Mr. Bill O'Brien for data management and programming.	Registry data supported by grants from the National Cancer Institute #HHSN2612013000121, and the Centers for Disease Control and Prevention #DP12-1205 DP003899-02
NARECHEM-ST (Greece)	Nick Dessypris for the statistical analysis of the data. NARECHEM-ST group: Margarita Baka, Maria Moschovi, Vassilios Papadakis, Sophia Polychronopoulou, Maria Kourti, Emmanuel Hatzipantelis, Eftichia Stiakaki, Helen Dana	NARECHEM-ST was partially supported by the Hellenic Society for Social Pediatrics and Health Promotion.
SETIL working group (Italy)	The SETIL (Italian Multicentric Epidemiological Study on Risk Factors of Childhood Leukaemia, Non-Hodgkin Lymphoma and Neuroblastoma) Working Group: Corrado Magnani and Alessandra Ranucci (Cancer Epidemiology Unit, CPO Piedmont Novara); Assunta Rasulo (CPO Piedmont, Torino); Lucia Miligi, Alessandra Benvenuti, Patrizia Legittimo and Angela Veraldi (Occupational and Environmental Unit, ISPO, Firenze); Antonio Acquaviva (AOU Siena); Maurizio Aricò, Alma Lippi and Gabriella Bernini (AOU Meyer, Firenze); Giorgio Assennato (ARPA, Bari); Stefania Varotto and Paola Zambon (Università di Padova); Pierfranco Biddau and Roberto Targhetta (Ospedale Microcitemico, Cagliari); Luigi Bisanti and Giuseppe Sampietro (ASL di Milano); Francesco Bochicchio, Susanna Lagorio, Cristina Nuccetelli, Alessandro Polichetti and Serena Risica, (ISS, Roma); Santina Cannizzaro and Lorenzo Gafà (LILT, Ragusa); Egidio Celentano (ARSan, Napoli); Pierluigi Cocco (Università di Cagliari); Marina Cuttini (IRCCS Burlo Garofolo, Trieste); Francesco Forastiere, Ursula Kirchmayer and Paola Michelozzi (Dipartimento Epidemiologia Regione Lazio, Roma); Erni Guarino (INT Napoli); Riccardo Haupt (Istituto Giannina Gaslini, Genova); Franco Locatelli (Università di Pavia and AO Bambin Gesù, Roma); Lia Lidia Luzzatto (ASL 1, Torino); Giuseppe Masera (Università Milano Bicocca, Monza); Pia Massaglia (Università di Torino); Stefano Mattioli and Andrea Pession (Università di Bologna); Domenico Franco Merlo and Vittorio Bocchini (IST, Genova); Liliana Minelli and Manuela Chiavarini (Università degli Studi di Perugia); Margherita Nardi (AOU Pisa); Paola Mosciatti and Franco Pannelli (Università di Camerino); Vincenzo Poggi (AORN Santobono, Pausilipon, Napoli); Alessandro Pulsoni (Sapienza University, Roma); Carmelo Rizzari (AO San Gerardo, Monza); Roberto Rondelli (Policlinico S. Orsola, Bologna); Gino Schilirò (Università di Catania); Alberto Salvan (IASI-CNR, Roma); Maria Valeria Torregrossa and Rosaria Maria Valenti (Università degli Studi di Palermo); Alessandra Greco, Gian Luca DeSalvo and Daniele Monetti (IOV-IRCCS,	The SETIL study was financially supported by research grants received by AIRC (Italian Association on Research on Cancer), MIUR (Ministry for Instruction, University and Research, PRIN Program), Ministry of Health (Ricerca Sanitaria Finalizzata Program), Ministry of Labour and Welfare, Associazione Neuroblastoma, Piemonte Region (Ricerca Sanitaria Finalizzata Regione Piemonte Program), Liguria Region, Comitato per la vita Daniele Chianelli- Associazione per la Ricerca e la Cura delle Leucemie, Linfomi e Tumori di Adulti e Bambini, (Perugia), "5 per 1000 2013" to IRCCS AOU San

	Padova); Claudia Galassi (San Giovanni Battista Hospital, Torino); Veronica Casotto (IRCCS Burlo Garofolo, Trieste); Gigliola de Nichilo (ASL BT, SPRESAL Barletta); Alberto Cappelli, (Accademia dei Georgofili, Florence).	
New York, Minnesota, California, Texas and Washington case-control studies	Investigators: Erin Marcotte, Logan Spector, Colleen McLaughlin, and Susan Carozza	This work was supported by Children’s Cancer Research Fund, Minneapolis, MN; National Cancer Institute at the National Institutes of Health (R01CA92670 to TX); and the Centers for Disease Control and Prevention’s National Program of Cancer Registries by cooperative agreement (U58DP000783-01 to NY).
UKCCS study	Investigators: Eve Roman, Eleanor Kane	Bloodwise, UK reference, 15037
German study	The authors would like to thank Drs Peter Kaatsch, Rolf Meinert, Uwe Kaletsch and Jörg Michaelis (University of Mainz) for their work in the original study.	The Data Coordination Center at the IARC is supported by a grant from Children with Cancer UK for which we are grateful. The German case-control study was funded by the German Federal Ministry for the Environment, Nature Conservation and Nuclear Safety.
New Zealand study (NZCCS)	GP Herbison, DCG Skegg and JM Elwood are thanked for their contributions to the original study.	The NZCCS was funded by the Health Research Council of NZ, the NZ Lottery Grants Board, the Otago Medical School (Faculty Bequest Funds), the Cancer Society of NZ, the Otago Medical Research Foundation, and the A.B. de Lautour Charitable Trust.
Danish study	Julia Heck	This work was supported by the US National Institutes of Health (R21CA175959, R03ES021643).
Finnish study		Competitive Research Funding of Pirkanmaa Hospital District (grant numbers 9R029 and 9S032 to Olli Lohi)
Childhood Leukemia International Consortium (CLIC)		Administration, annual meetings, and pooled analyses partially supported by the National Cancer Institute (NCI), USA (R03CA132172, Cancer Epidemiology Consortia), National Institute of Environmental Health Sciences (NIEHS), USA (P01ES018172, R01ES009137, R13ES021145, R13ES022868, R13ES024632, and U13ES026496), the US Environmental Protection Agency (USEPA), USA (RD83451101), CHILDREN with CANCER, UK, Alex’s Lemonade Stand Foundation (ALSF), São Paulo Research Foundation (FAPESP), Northwestern Mutual (NM), Texas Children’s Hospital (TCH), Childhood Cancer Research Fund (CCRF), and individual member study institutions. The content is solely the responsibility of the authors and does not necessarily represent the official views of the institutions named above

Supplementary Figure 1. Distribution of paternal and maternal age at birth of controls across the participating studies (ranked by questionnaire-based case-control followed by registry-based case-control studies)

